

Edgar Filing: NOVAMED EYECARE INC - Form 10-Q

NOVAMED EYECARE INC
Form 10-Q
May 14, 2002

=====

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED: MARCH 31, 2002

COMMISSION FILE NUMBER: 0-26625

NOVAMED EYECARE, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

36-4116193
(I.R.S. Employer Identification No.)

980 North Michigan Avenue, Suite 1620, Chicago, Illinois 60611
(Address of principal executive offices)

Registrant's telephone, including area code: (312) 664-4100

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

As of May 13, 2002, there were outstanding 24,877,548 shares of the registrant's common stock, par value \$.01 per share.

=====

NOVAMED EYECARE, INC.
FORM 10-Q FOR QUARTERLY PERIOD ENDED MARCH 31, 2002
INDEX

PART OR ITEM

Part I. FINANCIAL STATEMENTS

Edgar Filing: NOVAMED EYECARE INC - Form 10-Q

- Item 1. Interim Condensed Consolidated Financial Statements (unaudited)
 Condensed Consolidated Balance Sheets - March 31, 2002 and
 December 31, 2001
 Condensed Consolidated Statements of Operations - Three months ended
 March 31, 2002 and 2001
 Condensed Consolidated Statements of Cash Flows - Three months ended
 March 31, 2002 and 2001
 Notes to the Interim Condensed Consolidated Financial Statements
- Item 2. Management's Discussion and Analysis of Financial Condition and Results of
 Operations
- Part II. OTHER INFORMATION
- Item 6. Exhibits and Reports on Form 8-K
 Signatures

2

Part I
 Item 1.

NOVAMED EYECARE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS

(Dollars in thousands, except per share data)

	March 31, 2002	
ASSETS	-----	-----
Current assets:	(unaudited)	
Cash and cash equivalents	\$ 787	\$
Accounts receivable, net	7,829	
Notes and amounts due from affiliated providers	1,752	
Inventory	1,199	
Current tax assets, net	4,360	
Other current assets	728	
Current assets of discontinued operations	9,810	

Total current assets	26,465	
Property and equipment, net	7,326	
Intangible assets, net	21,832	
Noncurrent deferred tax assets, net	11,916	
Other assets, net	1,716	
Noncurrent assets of discontinued operations, net	9,547	

Total assets	\$ 78,802	\$
	=====	=====
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 3,429	\$
Accrued expenses	2,203	
Restructuring reserves	2,535	
Current maturities of long-term debt	54	
Current liabilities of discontinued operations	8,507	

Edgar Filing: NOVAMED EYECARE INC - Form 10-Q

Total current liabilities	----- 16,728 -----	
Long-term debt, net of current maturities	----- 12,419 -----	
Minority interest	----- 180 -----	
Commitments and contingencies		
Stockholders' equity:		
Series E Junior Participating Preferred Stock, \$0.01 par value, 1,912,000 shares authorized, none outstanding at March 31, 2002 and December 31, 2001, respectively	----- -- -----	
Common stock, \$0.01 par value, 81,761,465 shares authorized, 24,877,548 and 24,835,108 shares issued and outstanding at March 31, 2002 and December 31, 2001, respectively	249	
Additional paid-in-capital	77,699	
Retained earnings (deficit)	(28,439)	
Treasury stock	(34)	

Total stockholders' equity	49,475 -----	

Total liabilities and stockholders' equity	\$ 78,802 =====	\$ =====

The notes to the interim condensed consolidated financial statements are an integral part of these statements.

3

NOVAMED EYECARE, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands, except per share data; unaudited)

	Three months ended March 31,	
	----- 2002 -----	----- 2001 -----
Net revenue:		
Surgical facilities	\$ 8,244	\$
Product sales and other	8,649	
	-----	-----
Total net revenue	16,893 -----	
	-----	-----
Operating expenses:		
Salaries, wages and benefits	3,392	
Cost of sales and medical supplies	9,022	
Selling, general and administrative	2,288	
Depreciation and amortization	607	
	-----	-----
Total operating expenses	15,309	

Edgar Filing: NOVAMED EYECARE INC - Form 10-Q

Income from continuing operations	1,584	
Other expense, net	77	
Income from continuing operations before income taxes	1,507	
Income tax provision	603	
Net income from continuing operations before cumulative effect of change in accounting principle	904	
Net income (loss) from discontinued operations	(208)	
Cumulative effect of change in accounting principle, net of tax	(1,803)	
Net income (loss)	\$ (1,107)	\$
Basic earnings per common share:		
Income from continuing operations before cumulative effect of change in accounting principle	\$ 0.04	\$
Income (loss) from discontinued operations	(0.01)	
Cumulative effect of change in accounting principle	(0.07)	
Net income (loss)	\$ (0.04)	\$
Diluted earnings per common share:		
Income from continuing operations before cumulative effect of change in accounting principle	\$ 0.04	\$
Income (loss) from discontinued operations	(0.01)	
Cumulative effect of change in accounting principle	(0.07)	
Net income (loss)	\$ (0.04)	\$
Weighted average common shares outstanding	24,837	
Dilutive effect of employee stock options	--	
Diluted weighted average common shares outstanding	24,837	

The notes to the interim condensed consolidated financial statements are an integral part of these statements.

Edgar Filing: NOVAMED EYECARE INC - Form 10-Q

Cash flows from operating activities:	
Net income (loss)	\$ (1,107)
Adjustments to reconcile net income to net cash provided by continuing operations, net of effects of purchase transactions--	
Net (earnings) loss of discontinued operations	208
Cumulative effect of change in accounting principle, net	1,803
Depreciation and amortization	607
Minority interest	38
Deferred taxes	603
Changes in working capital items--	
Accounts receivable	(501)
Inventory	(37)
Other current assets	1,828
Accounts payable and accrued expenses	443
Other noncurrent assets	(45)

Net cash provided by operating activities	3,840

Cash flows from investing activities:	
Purchases of property and equipment	(299)
Issuance of notes receivable to affiliated providers	(12)

Net cash used by investing activities	(311)

Cash flows from financing activities:	
Borrowings under revolving line of credit	6,850
Payments under revolving line of credit	(15,145)
Proceeds from the issuance of common stock	27
Payments of other debt, debt issuance fees and capital lease obligations	(344)

Net cash used by financing activities	(8,612)

Cash flows from discontinued operations:	
Operating activities	1,915
Investing activities	3,000
Financing activities	(12)

Net cash provided by discontinued operation	4,903

Net increase (decrease) in cash and cash equivalents	(180)
Cash and cash equivalents, beginning of period	967

Cash and cash equivalents, end of period	\$ 787
	=====

The notes to the interim condensed consolidated financial statements are an integral part of these statements.

Edgar Filing: NOVAMED EYECARE INC - Form 10-Q

(Dollars in thousands, except per share data; unaudited)

1. BASIS OF PRESENTATION

The information contained in the interim consolidated financial statements and notes is condensed from that which would appear in the annual consolidated financial statements. Accordingly, the interim condensed consolidated financial statements included herein should be read in conjunction with the consolidated financial statements as of and for the year ended December 31, 2001, filed by NovaMed Eyecare, Inc. with the Securities and Exchange Commission on Form 10-K. The unaudited interim condensed consolidated financial statements as of March 31, 2002 and for the three months ended March 31, 2002 and 2001, include all normal recurring adjustments which management considers necessary for a fair presentation. The results of operations for the interim periods are not necessarily indicative of the results that may be expected for the entire fiscal year.

Prior year amounts have been reclassified to conform to current year presentation as further discussed in Note 3 below.

2. GOODWILL AND OTHER INTANGIBLE ASSETS -- CUMULATIVE EFFECT OF CHANGE IN ACCOUNTING PRINCIPLE

Effective January 1, 2002 we adopted Statement of Financial Accounting Standards No. 142, "Goodwill and Other Intangible Assets" (FAS 142). Under the new rules, we are no longer required to amortize goodwill and other intangible assets with indefinite lives. We will be required to subject these assets to periodic testing for impairment. Impairment losses for goodwill and indefinite-lived intangible assets that arise due to the initial application of FAS 142 are required to be reported as resulting in a change in accounting principle.

We performed an evaluation of all our existing goodwill as of January 1, 2002 and determined that the goodwill associated with one of our ancillary businesses was impaired. This business sells marketing products to the laser vision correction market, which has lately shown a downturn in demand. This downturn has negatively impacted the prospects for this business. We are in the process of developing new products at this business to diversify its revenue base. The business was evaluated using an expected cash flow valuation method which indicated that the carrying value of the business had been impaired by approximately \$2.9 million. We recorded a net of tax charge of \$1.8 million to write-off a portion of acquired goodwill in our first quarter financial statements as a change in accounting principle. All intangible assets are reported in our Corporate segment.

The intangible assets that are continuing to be amortized over 25 years are related to the Management Services Agreements at our remaining optical dispensaries.

	Unamortized Intangible Assets	Amortized Intangible Assets
	-----	-----
Balance as of December 31, 2001	\$ 24,099	\$ 652
Initial impairment upon adoption of FAS 142	(2,911)	--
Amortization expense	--	(8)
	-----	-----
Balance as of March 31, 2002	\$ 21,188	\$ 644
	=====	=====

Edgar Filing: NOVAMED EYECARE INC - Form 10-Q

6

NOVAMED EYECARE, INC. AND SUBSIDIARIES
 NOTES TO THE INTERIM
 CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
 March 31, 2002
 (Dollars in thousands, except per share data; unaudited)

The following tables summarize the results of continuing operations and earnings per share had FAS 142 been adopted at the beginning of 2001:

	Three Months ended March 31, 2001

Reported income from continuing operations	\$ 464
Add back: Goodwill amortization	253
Less: Related tax effect	(64)

Adjusted income from continuing operations	\$ 653
	=====

Three months ended March 31, 2001	Basic Earnings Per Share	Diluted Earnings Per Share
-----	-----	-----
Reported net income from continuing operations	\$ 0.02	\$ 0.02
Goodwill amortization	0.01	0.01
	-----	-----
Adjusted net income from continuing operations	\$ 0.03	\$ 0.03
	=====	=====

3. DISCONTINUED OPERATIONS

As required, effective January 1, 2002 we adopted Statement of Financial Accounting Standards No. 144, "Accounting for the Impairment or Disposal of Long-lived Assets" ("FAS 144") under which we will report as discontinued operations certain entities that have been disposed of or are classified as held for sale. Under FAS 144 projected operating results and the estimated gain or loss on sale is no longer accrued for when the decision to sell is made. Rather, the earnings or losses of discontinued operations continue to be reported, and any gain or loss is recognized at the time of sale. In the first quarter of 2002, we sold an ambulatory surgery center and an optical dispensary business, both of which are reported as discontinued operations under the provisions of FAS 144. Prior period financial statements have been restated to reflect these entities as discontinued.

During 2001, we implemented a Plan of Discontinued Operations and Restructuring (the "Plan"). This involves the divestiture of the management services segment or physician practice management ("PPM") business. The results of these discontinued operations are accounted for under APB Opinion No. 30 "Reporting the Results of Operations -- Reporting the Effects of Disposal of a

Edgar Filing: NOVAMED EYECARE INC - Form 10-Q

Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions" ("APB 30"). Under APB 30, the projected operating results and the estimated gain or loss on disposal was accrued for at the date the plan was adopted. We reported a charge of \$27.2 million, net of tax in our third quarter 2001 financial statements. To date, we have completed five of eighteen planned divestiture transactions. We received total proceeds of \$5.1 million, consisting of \$4.0 million in cash and \$1.1 million in promissory notes with multi-year terms.

Net interest expense allocated to discontinued operations was \$93,000 and \$309,000 for the three months ended March 31, 2002 and 2001, respectively. Interest was allocated to discontinued operations accounted for under APB 30, based on the proportion of net assets of discontinued operations to consolidated net assets plus consolidated debt as prescribed by EITF 87-24 -- Allocation of Interest to Discontinued Operations.

7

NOTES TO THE INTERIM
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
March 31, 2002
(Dollars in thousands, except per share data; unaudited)

The operating results of all discontinued operations are summarized below.

	Three months ended March 31,	
	2002	2001
Net revenue	\$ 15,338	\$ 19,724
Operating expenses	14,860	18,174
Interest and other expense, net	73	305
	405	1,245
Income from operations before income taxes		
Income tax provision	162	531
	243	714
Net income from operations		
Loss on sale of discontinued operations	(310)	--
Income tax benefit	118	--
	(192)	--
Net loss on sale of discontinued operations		
Net income from discontinued operations	\$ 51	\$ 714

During the first quarter of 2002, \$259,000 of the net income was credited to the discontinued operations reserves, which resulted in a reported net loss of \$208,000 for the period.

The balance sheet components of discontinued operations are summarized as follows:

	March 31, 2002	December 31, 2001
	-----	-----

Edgar Filing: NOVAMED EYECARE INC - Form 10-Q

Accounts and notes receivable	\$ 8,630	\$ 13,869
Inventories	598	1,203
Other current assets	582	718
	-----	-----
Current assets of discontinued operations	\$ 9,810	\$ 15,790
	=====	=====
Net property and equipment	\$ 4,772	\$ 5,455
Intangible assets	4,775	7,234
	-----	-----
Noncurrent assets of discontinued operations	\$ 9,547	\$ 12,689
	=====	=====
Accounts payable	\$ 1,140	\$ 1,174
Accrued expenses	1,980	2,591
Notes payable and capitalized lease obligations	29	78
Discontinued operations reserves	5,358	5,242
	-----	-----
Current liabilities of discontinued operations	\$ 8,507	\$ 9,085
	=====	=====

Included in the balance sheet caption "Discontinued operations reserves" at March 31, 2002 are reserves of \$2.1 million for projected operating results and estimated gain or loss on disposal and \$3.3 million for costs to exit the PPM business.

8

NOVAMED EYECARE, INC. AND SUBSIDIARIES
NOTES TO THE INTERIM
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
March 31, 2002
(Dollars in thousands, except per share data; unaudited)

4. RESTRUCTURING RESERVES

During the first quarter of 2002, we terminated a contract to purchase an ASC and negotiated the sublease of one closed LVC center.

	Reserve at December 31, 2001	Charges Utilized	Reserve at March 31, 2002
	-----	-----	-----
Facility closures--			
Asset impairments	\$ 905	\$ (212)	\$ 693
Lease commitments	1,717	(543)	1,174
Contract termination	1,836	(1,702)	134
Reorganization of IT--			
Asset impairments	12	--	12
Lease commitments	456	--	456
Other	97	(31)	66
	-----	-----	-----
Total reserve balance	\$ 5,023	\$ (2,488)	\$ 2,535
	=====	=====	=====

Edgar Filing: NOVAMED EYECARE INC - Form 10-Q

5. REVOLVING CREDIT FACILITY

At March 31, 2002, we had \$12.4 million outstanding under our revolving credit facility that expires on June 30, 2003. The maximum commitment available under the facility was \$40.0 million at April 1, 2002 and will be reduced by \$2.5 million per quarter, resulting in a maximum commitment of \$35.0 million as of October 1, 2002.

Under the facility, interest on borrowings under the credit agreement is payable at an annual rate equal to the lender's published base rate plus the applicable borrowing margin ranging from 0% to 1.0% or LIBOR plus a range from 1.5% to 3.0%, varying upon our ability to meet financial covenants. The weighted average interest rate on credit line borrowings was 4.7% for three months ended March 31, 2002 and 4.2% at March 31, 2002. The credit agreement contains covenants that include limitations on indebtedness, liens, capital expenditures, acquisitions and affiliations and ratios that define borrowing availability and restrictions on the payment of dividends. We are required to use 100% of the proceeds from our divestiture transactions to pay down outstanding debt.

We amended our credit agreement on February 5, 2002 to include additional covenants. We will be in default if our cash expenditures incurred in connection with the Plan (including, without limitation, the costs of structuring and negotiating the divestiture transactions, terminating employees and closing facilities), exceeds by \$10 million the sum of EBITDA from the discontinued management services operations plus the cash proceeds from these transactions. As of March 31, 2002, we were in compliance with all our credit agreement covenants.

9

NOVAMED EYECARE, INC. AND SUBSIDIARIES
NOTES TO THE INTERIM
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
March 31, 2002
(Dollars in thousands, except per share data; unaudited)

6. OPERATING SEGMENTS

The table below presents information about operating data and segment assets as of and for the three months ended March 31, 2002 and 2001 (in thousands):

	Surgical Facilities	Product Sales and Other	Corporate	To
	-----	-----	-----	-----
Three months ended March 31, 2002				

Net revenue	\$ 8,244	\$ 8,649	\$ --	\$
Earnings (loss) before tax	2,632	523	(1,648)	
Depreciation and amortization	469	69	69	
Interest income	1	--	26	
Interest expense	1	--	134	
Identifiable assets	9,454	5,695	63,653	
	=====	=====	=====	=====
Three months ended March 31, 2001				

Edgar Filing: NOVAMED EYECARE INC - Form 10-Q

Net revenue	\$	9,707	\$	7,447	\$	--	\$
Earnings (loss) before tax		3,382		745		(3,321)	
Depreciation and amortization		475		60		593	
Interest income		--		2		23	
Interest expense		--		--		308	
Identifiable assets		13,815		6,118		103,047	
		=====		=====		=====	=====

10

Item 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The discussion below contains forward-looking statements (as such term is defined in Section 21E of the Securities Exchange Act of 1934) that are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. Our results, performance and achievements in 2002 and beyond could differ materially from those expressed in, or implied by, any such forward looking statements. See "Cautionary note regarding forward-looking statements" on page 14.

Outlook

We provide a comprehensive range of eye care services, focused primarily around our surgical facilities, including our ownership and operation of 15 ambulatory surgery centers (ASCs), and our operation of 13 laser vision correction centers and fixed-site laser services agreements. Eye care professionals perform laser vision correction, cataract and other eye-related surgical procedures in the surgical facilities we own and/or operate.

The discussion set forth below analyzes certain factors and trends related to the financial results of continuing operations for each of the three months ended March 31, 2002 and 2001. This discussion should be read in conjunction with the condensed consolidated financial statements and notes to the condensed consolidated financial statements above.

Results of Operations

Three Months Ended March 31, 2002 Compared to the Three Months Ended March 31, 2001

Net Revenue. Net revenue decreased 1.7% from \$17.2 million to \$16.9 million. Surgical facilities net revenue decreased 15.5% from \$9.7 million to \$8.2 million primarily due to the decrease in surgical procedures performed as well as the change in surgical procedure mix. During the first quarter of 2002, total surgical procedures performed in our surgical facilities decreased 18.7% to 10,013. LVC procedures decreased 42.8%, cataract procedures increased 4.6% and other procedures decreased 6.0%, compared to 2001. Management believes that the demand for elective LVC surgery continues to be negatively impacted by the general economic conditions. The majority of the increase in cataract procedures came from our Thibodaux, LA ASC, which we acquired in November of 2001.

Product sales and other net revenue increased 16.2% from \$7.4 million to \$8.6 million, primarily as a result of a 27.1% net revenue increase at our optical products purchasing organization coupled with an 8.3% increase in net revenue at our optical laboratories. The increase was offset by a 35.0% decrease in net revenue at our optical dispensaries and a 24.6% decrease in net revenue

Edgar Filing: NOVAMED EYECARE INC - Form 10-Q

at our marketing products business. The increase in net revenue at our optical products purchasing organization and optical laboratories was primarily due to the addition of new customers and increased sales to existing customers. Approximately 70% of the decrease in net revenue from our optical dispensaries was due to the closing of optical dispensaries in 2001. We experienced a 14.2% decline in sales at our remaining optical dispensaries. Our marketing products business has sold products primarily to the laser vision correction market. The downturn in this market was the cause of the decline in net revenue and led us to take a \$1.8 million net charge to write off a portion of the carrying value of goodwill created when we acquired the company in 2000. This charge is reported as a change in accounting principle.

Salaries, Wages and Benefits. Salaries, wages and benefits expense decreased 24.4% from \$4.5 million to \$3.4 million. As a percentage of net revenue, salaries, wages and benefits expense decreased from 26.0% to 20.1%. The decrease in salaries, wages and benefits expense is a result of staff reductions at some surgical facilities in response to the reduction in LVC procedures as well as corporate staff reductions. Approximately 2.8% of the reduction is the result of closing several LVC centers and optical dispensaries in the fourth quarter of 2001. In addition, certain corporate salaries were charged to the discontinued operations reserves during the first quarter of 2002.

11

Cost of Sales and Medical Supplies. Cost of sales and medical supplies expense increased 13.9% from \$7.9 million to \$9.0 million. As a percentage of net revenue, cost of sales and medical supplies expense increased from 46.2% to 53.4%. The absolute increase in cost of sales and medical supplies expense is primarily a result of higher sales volumes at our optical products purchasing organization. The increase in cost of sales and medical supplies as a percentage of net revenue is due to our product sales and other segment net revenue increasing to 51.2% of total net revenue in the first quarter of 2002, up from 43.4% in 2001. This segment has a much higher cost of sales and medical supplies expense relative to net revenue than our surgical facilities segment.

Selling, General and Administrative. Selling, general and administrative expense ("SG&A") decreased 4.2% from \$2.4 million to \$2.3 million. As a percentage of net revenue, SG&A expense decreased from 14.2% to 13.5%. The absolute decrease in selling, general and administrative expense is the result of closing several LVC centers and optical dispensaries in the fourth quarter of 2001. Excluding those closures, SG&A was flat compared to the prior year quarter.

Depreciation and Amortization. Depreciation and amortization expense decreased 45.5% from \$1.1 million to \$607,000. The cessation of goodwill amortization as of January 1, 2002 contributed \$253,000 of this decrease as compared to the same quarter of 2001. The remainder of the decrease is due to the write-off of assets at the end of our 2001 third quarter in our restructuring plan.

Other Expense. Other expense decreased from \$410,000 to \$77,000. The decrease in other expense was primarily related to a decrease in interest expense as a result of lower average interest rates during the first quarter of 2002 (4.7%) as compared to the 2001 period (7.9%) as well as lower average borrowings of \$18.8 million during the first quarter of 2002 as compared to \$28.5 million during the first quarter of 2001. In addition, the first quarter of 2001 included \$129,000 of losses from a nonconsolidated affiliate. Our investment in that entity was reduced to zero within our restructuring plan.

Provision for Income Taxes. The adoption of FAS 142 reduced our effective

Edgar Filing: NOVAMED EYECARE INC - Form 10-Q

tax rate to 40.0% from 42.4% in the first quarter of 2001. Under the new accounting pronouncement we no longer amortize most of our goodwill which substantially reduces the amount of permanent differences in our tax calculation.

Liquidity and Capital Resources

Net cash provided by continuing operating activities was \$3.8 million and \$1.1 million for the three months ended March 31, 2002 and 2001, respectively. This included a \$1.5 million refund of 2001 estimated federal tax payments. We used \$311,000 of cash for investing activities during the first three months of 2002, primarily for the purchase of equipment. During the first three months of 2002, our net borrowings under our revolving credit line decreased \$8.3 million from the December 31, 2001 level, using cash generated by operations and proceeds from divestiture transactions. At March 31, 2002, we had working capital of \$ 11.0 million (excluding restructuring and discontinued operations reserves).

During the first quarter of 2002, we completed four planned divestiture transactions. We received total proceeds of \$4.0 million, consisting of \$3.2 million in cash and a \$750,000 promissory note with a multi-year term. The cash proceeds were used to reduce debt as required under our revolving credit facility.

On May 6, 2002 we announced that we had entered into a definitive agreement to acquire a majority interest in an ambulatory surgery center in Colorado Springs, Colorado. We expect to close on this acquisition in late May following state licensure approvals.

At March 31, 2002, we had \$12.4 million outstanding under our revolving credit facility that expires on June 30, 2003. The maximum commitment available under the facility was \$40.0 million at April 1, 2002 and will be reduced by \$2.5 million per quarter, resulting in a maximum commitment of \$35.0 million as of October 1, 2002.

Under the facility, interest on borrowings under the credit agreement is payable at an annual rate equal to the lender's published base rate plus the applicable borrowing margin ranging from 0% to 1.0% or LIBOR plus a range from 1.5% to 3.0%, varying upon our ability to meet financial covenants. The weighted average interest rate

12

on credit line borrowings was 4.7% for three months ended March 31, 2002 and 4.2% at March 31, 2002. The credit agreement contains covenants that include limitations on indebtedness, liens, capital expenditures, acquisitions and affiliations and ratios that define borrowing availability and restrictions on the payment of dividends. We are required to use 100% of the proceeds from our divestiture transactions to pay down outstanding debt.

We amended our credit agreement on February 5, 2002 to include additional covenants. We will be in default if our cash expenditures incurred in connection with the Plan (including, without limitation, the costs of structuring and negotiating the divestiture transactions, terminating employees and closing facilities), exceeds by \$10 million the sum of EBITDA from the discontinued management services operations plus the cash proceeds from these transactions. As of March 31, 2002, we were in compliance with all our credit agreement covenants.

Edgar Filing: NOVAMED EYECARE INC - Form 10-Q

We believe that our cash flow from operations and funds available under our existing revolving credit facility will be sufficient to fund our operations for at least 12 months. Our future capital requirements and the adequacy of our available funds will depend on many factors, including the timing of our acquisition activities, capital requirements associated with our surgical facilities, expansion and the future cost of surgical equipment, and cost of completing our discontinued operations plan. We also expect the cash proceeds from divestitures to supplement our cash flow.

One of our former affiliated eye care professionals has the option, exercisable beginning January 1, 2001 through January 1, 2006, to acquire up to a 30% interest in one of our ASCs. We have also entered into an agreement, subject to state licensure approvals, to sell a 20% interest in one of our ASCs to two former affiliated eye care professionals. One of our partners in an ASC in which we own a majority interest has the right to sell us up to a 10% interest in the ASC in November 2004 and up to an additional 10% interest in November 2006.

On June 15, 2000, we entered into an agreement to acquire two ASCs, contingent upon the resolution of certain requirements associated with the seller. Certain of these contingencies were satisfied in 2000 with respect to one of the ASCs, which we acquired in December 2000. Effective January 2002, we have terminated our agreement to acquire the second ASC, and have sold back to the seller the ASC acquired in December 2000.

13

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS. This Form 10-Q contains certain forward-looking statements that reflect our current expectations about our future results of operations, performance and achievements. When used in the Form 10-Q, the words "anticipates," "believes," "estimates," "plans," "intends," and similar expressions, as they relate to us or our management, are intended to identify such forward-looking statements. These forward-looking statements reflect our current beliefs and are based on information currently available to us. Accordingly, these statements are subject to certain risks and uncertainties which could cause our actual results, performance or achievements in 2002 and beyond to differ materially from those expressed in, or implied by, such statements. These risks and uncertainties include: our ability to grow or manage our growth; our ability to acquire, develop or manage a sufficient number of profitable surgical facilities; reduced prices and reimbursement rates for surgical procedures; the continued acceptance of laser vision correction and other refractive surgical procedures; demand for elective surgical procedures generally and in response to a protracted economic downturn; our ability to successfully implement our discontinued operations plan on acceptable terms consistent with our credit facility; and the application of existing or proposed government regulations. See "Management's Discussion and Analysis of Financial Conditions and Results of Operations - Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2001 for further discussion. We undertake no obligation to update or revise any such forward-looking statements that may be made to reflect events or circumstances after the date of this Form 10-Q or to reflect the occurrence of unanticipated events.

PART II. OTHER INFORMATION

Item 6. Exhibits and Reports on Form 8-K

- A. Exhibits
 - Exhibit 10.29*-- First Amendment to Second Amended and Restated Credit Agreement

Edgar Filing: NOVAMED EYECARE INC - Form 10-Q

B. Reports on Form 8-K
We did not file any reports on Form 8-K during the first quarter of 2002.

* Portions of this Exhibit have been omitted based upon a request for confidential treatment of this document; omitted portions have been separately filed with the Commission.

14

SIGNATURE

Pursuant to the requirement of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

NOVAMED EYECARE, INC.

/s/ Scott T. Macomber

May 14, 2002

Scott T. Macomber
Executive Vice President and
Chief Financial Officer
(on behalf of Registrant and as principal financial officer)

Date

/s/ Robert L. Hiatt

May 14, 2002

Robert L. Hiatt
Vice President Finance
(principal accounting officer)

Date

15